sur DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies to Engage in ACAAI 2024 Congress
DBV Technologies, a clinical-stage biopharmaceutical company, has announced its participation in the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting. This event, set between October 24-28, 2024 in Boston, Massachusetts, will include a "Product Theater" session focused on optimal peanut allergy treatments, featuring key experts like Drs. Shahzad Mustafa and Edwin Kim, among others. Additionally, DBV will sponsor the 33rd Annual FIT Bowl, a competition on allergy knowledge.
Dr. Pharis Mohideen, Chief Medical Officer, highlighted the company's progress with the Viaskin® Peanut patch for children. Despite ongoing regulatory processes, DBV remains dedicated to addressing peanut allergy treatment needs. The Viaskin Peanut patch is a product candidate aiming to mitigate allergic reactions through epicutaneous immunotherapy.
While the Viaskin Peanut patch's safety and efficacy are yet to be confirmed by relevant authorities, DBV continues to engage the medical community to foster progress in allergy treatment.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de DBV TECHNOLOGIES